CRX 103
Alternative Names: CRX-103Latest Information Update: 02 Jul 2023
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antineoplastics
- Mechanism of Action DNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 12 Jul 2005 Corixa Corporation has been acquired and merged into GlaxoSmithKline
- 13 Nov 2001 New profile
- 13 Nov 2001 Preclinical development for Cancer in USA (IV)